WCLC 2025 - Posters & ePosters-EP.13.21 Extended Follow-Up of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: Real-World Multicenter Study

EP.13.21 Extended Follow-Up of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: Real-World Multicenter Study

Back to course

Pdf Summary

This prospective, multicenter real-world study from South Korea evaluated the long-term effectiveness, prognostic factors, subsequent treatment patterns, and local therapy roles in 100 extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line atezolizumab combined with carboplatin/etoposide, following the IMpower-133 protocol. With a median follow-up of 26 months, the study demonstrated favorable outcomes compared to the original IMpower-133 clinical trial.<br /><br />Key findings include a median overall survival (OS) of 17.1 months versus 12.3 months in IMpower-133, and a median progression-free survival (PFS) of 6.2 months compared to 5.2 months. The objective response rate was 75%, and the disease control rate was 91%, both higher than in IMpower-133. The 1-year OS rate was 62.5%, exceeding the 51.7% reported in the clinical trial.<br /><br />Local therapies such as thoracic and brain radiotherapy (RT) demonstrated survival benefits. Brain RT was recommended for all patients presenting with brain metastases, while thoracic RT improved outcomes particularly in patients responding to systemic immunochemotherapy. Additionally, subsequent chemotherapy after progression extended survival, underscoring the importance of continuing treatment post-progression.<br /><br />In conclusion, this real-world study confirms the long-term effectiveness of atezolizumab combined with chemotherapy for ES-SCLC and highlights the adjunctive benefits of local radiotherapies and sequential systemic treatments to improve patient survival. These findings support integrating localized RT and considering ongoing therapies after progression in routine clinical practice for ES-SCLC management. The study was funded by Roche Korea.

Asset Subtitle

Yechan Song

Meta Tag

Speaker Yechan Song

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

extensive-stage small cell lung cancer

ES-SCLC

atezolizumab

carboplatin

etoposide

IMpower-133 protocol

overall survival

progression-free survival

thoracic radiotherapy

brain radiotherapy